ITGAL
Integrin alpha-L
As of the edition of 20 October 2026, ITGAL (integrin alpha-L, UniProt P20701) has 2 drugs tested at it and 4 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P20701
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 41
- Disease areas
- Eye; Skin and connective tissue; Immune system; Hormones; Nutrition and metabolism; Bones, joints and muscles; Inherited and neonatal; Mouth and teeth
- Registered trials of its drugs
- 64
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Withdrawn from market | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Efalizumab | Withdrawn from market | Phase 4 | Ended 2015 |
| Lifitegrast | Marketed | Phase 4 | Ends 2030 |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Undetermined | 2 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Bausch Health | Route B |
| Roche | Route A |
The other 2 companies at ITGAL
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at ITGAL, ranked, with the facts behind eachRequest access. Nothing is shown until you do.